Study of Ruxolitinib in Colorectal Cancer Patients

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is metastatic. * Previous treatment with fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapy, an anti-VEGF therapy (if no contraindication) and if KRAS wild type and no contraindication, an anti-EGFR therapy. * Radiographically measurable or evaluable disease (per RECIST v1.1) * Life expectancy of ≥ 12 weeks. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Three or more weeks have elapsed from the completion of previous treatment regimen and subjects must have recovered or be at a new stable baseline from any related toxicities. * Prior radiotherapy to disease sites is allowed with certain protocol-defined restrictions. Exclusion Criteria: * Prior treatment with regorafenib. * Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. * Active peptic ulcer disease, inflammatory bowel disease (eg, ulcerative colitis, Crohn's disease), diverticulitis, or other gastrointestinal conditions with increased risk of perforation or gastrointestinal bleeding. * Recent history (≤ 3 months) or ongoing partial or complete bowel obstruction unless due to disease under study and corrected with surgery. * Blood pressure ≥ 140/90 mmHg. * Active bleeding diathesis or history of any major bleeding (eg, requiring transfusion of red blood cells (RBCs), central nervous system (CNS) bleeding, or significant hemoptysis within 6 months of enrollment. Subjects with bleeding secondary to underlying disease (including gastrointestinal (GI) perforation or fistula) that has been corrected by surgery or alternative procedure may be included. * Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class II, III, or IV congestive heart failure, and arrhythmia requiring therapy.